• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Surfactant replacement therapy for respiratory distress syndrome in preterm infants: United Kingdom national consensus.

作者信息

Banerjee Sujoy, Fernandez Ramon, Fox Grenville F, Goss Kevin C W, Mactier Helen, Reynolds Peter, Sweet David G, Roehr Charles C

机构信息

Singleton Hospital, Swansea, UK.

Royal Sussex County Hospital, Brighton, UK.

出版信息

Pediatr Res. 2019 Jul;86(1):12-14. doi: 10.1038/s41390-019-0344-5. Epub 2019 Feb 19.

DOI:10.1038/s41390-019-0344-5
PMID:30780152
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6760556/
Abstract
摘要

相似文献

1
Surfactant replacement therapy for respiratory distress syndrome in preterm infants: United Kingdom national consensus.早产儿呼吸窘迫综合征的表面活性剂替代疗法：英国国家共识
Pediatr Res. 2019 Jul;86(1):12-14. doi: 10.1038/s41390-019-0344-5. Epub 2019 Feb 19.
2
Surfactant therapy in preterm infants with respiratory distress syndrome and in near-term or term newborns with acute RDS.用于患有呼吸窘迫综合征的早产儿以及患有急性呼吸窘迫综合征的近足月儿或足月儿的表面活性剂治疗。
J Perinatol. 2006 May;26 Suppl 1(Suppl 1):S51-6; discussion S63-4. doi: 10.1038/sj.jp.7211474.
3
The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation.OPTIMIST - A试验：对妊娠25 - 28周早产儿进行微创表面活性剂治疗的评估。
BMC Pediatr. 2014 Aug 27;14:213. doi: 10.1186/1471-2431-14-213.
4
Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome.含蛋白质的合成表面活性剂与动物源性表面活性剂提取物用于预防和治疗呼吸窘迫综合征的比较
Cochrane Database Syst Rev. 2007 Oct 17(4):CD006069. doi: 10.1002/14651858.CD006069.pub3.
5
Surfactant therapy: past, present and future.表面活性物质治疗：过去、现在和未来。
Early Hum Dev. 2013 Jun;89 Suppl 1:S22-4. doi: 10.1016/S0378-3782(13)70008-2.
6
On "A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants" (Am J Perinatol 2004;21:109-120).关于“一项在早产儿呼吸窘迫综合征治疗中，肺泡表面活性物质（珂立苏）与贝乐可（固尔苏）的随机、多中心、双盲对照试验”（《美国围产医学杂志》2004年；21卷：第109 - 120页）
Am J Perinatol. 2004 Jul;21(5):307-9. doi: 10.1055/s-2004-829876.
7
A pilot study of evaluation of semi-rigid and flexible catheters for less invasive surfactant administration in preterm infants with respiratory distress syndrome-a randomized controlled trial.一项评价早产儿呼吸窘迫综合征应用半刚性和软性导管行微创表面活性剂给药的初步研究——一项随机对照试验。
BMC Pediatr. 2022 Nov 4;22(1):637. doi: 10.1186/s12887-022-03714-3.
8
Cost-saving effect of early less invasive surfactant administration versus continuous positive airway pressure therapy alone for preterm infants with respiratory distress syndrome.早期使用较少侵袭性表面活性剂治疗与单独持续气道正压通气治疗对有呼吸窘迫综合征的早产儿的成本节约效果。
Eur J Hosp Pharm. 2022 Nov;29(6):346-352. doi: 10.1136/ejhpharm-2020-002465. Epub 2021 Mar 3.
9
Synthetic Surfactant CHF5633 Compared with Poractant Alfa in the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial.合成表面活性剂CHF5633与固尔苏治疗新生儿呼吸窘迫综合征的多中心、双盲、随机对照临床试验
J Pediatr. 2020 Oct;225:90-96.e1. doi: 10.1016/j.jpeds.2020.06.024. Epub 2020 Jun 14.
10
Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome.含蛋白质的合成表面活性剂与动物源性表面活性剂提取物用于预防和治疗呼吸窘迫综合征的比较
Cochrane Database Syst Rev. 2007 Jul 18(3):CD006069. doi: 10.1002/14651858.CD006069.pub2.

引用本文的文献

1
Quantitative lung ultrasound to guide surfactant retreatment in preterm neonates born at ≤30 weeks' gestation: a multicentre retrospective non-inferiority diagnostic accuracy study.定量肺部超声指导胎龄≤30周早产儿表面活性剂再治疗：一项多中心回顾性非劣效性诊断准确性研究。
EBioMedicine. 2025 Jul 25;118:105865. doi: 10.1016/j.ebiom.2025.105865.
2
Surfactant Therapy in Late Preterm Infants with Respiratory Distress in Türkiye: An Observational, Prospective, Multicenter Study.土耳其晚期早产儿呼吸窘迫的表面活性剂治疗：一项观察性、前瞻性、多中心研究。
Turk Arch Pediatr. 2025 Mar 3;60(2):164-171. doi: 10.5152/TurkArchPediatr.2025.24236.
3
Less Invasive Surfactant Administration for Preterm Infants - State of the Art.经鼻给予早产儿表面活性物质治疗——最新进展。
Neonatology. 2024;121(5):584-595. doi: 10.1159/000540078. Epub 2024 Sep 3.
4
Relationship between neonatal respiratory distress syndrome pulmonary ultrasonography and respiratory distress score, oxygenation index, and chest radiography grading.新生儿呼吸窘迫综合征肺部超声检查与呼吸窘迫评分、氧合指数及胸部X线分级之间的关系
World J Clin Cases. 2024 Jul 16;12(20):4154-4165. doi: 10.12998/wjcc.v12.i20.4154.
5
Association of Fetal Lung Development Disorders with Adult Diseases: A Comprehensive Review.胎儿肺发育障碍与成人疾病的关联：综述
J Pers Med. 2024 Mar 29;14(4):368. doi: 10.3390/jpm14040368.
6
High vs low CPAP strategy with aerosolized calfactant in preterm infants with respiratory distress syndrome.高与低持续气道正压通气策略联合雾化牛肺表面活性剂用于呼吸窘迫综合征早产儿的研究
J Perinatol. 2025 Jan;45(1):73-76. doi: 10.1038/s41372-024-01959-7. Epub 2024 Apr 9.
7
Less invasive surfactant administration methods: Who, what and how.更微创的表面活性物质给药方法：谁、什么和如何。
J Perinatol. 2024 Apr;44(4):472-477. doi: 10.1038/s41372-023-01778-2. Epub 2023 Sep 22.
8
Artificial Intelligence-Driven Respiratory Distress Syndrome Prediction for Very Low Birth Weight Infants: Korean Multicenter Prospective Cohort Study.人工智能驱动的极低出生体重儿呼吸窘迫综合征预测：韩国多中心前瞻性队列研究。
J Med Internet Res. 2023 Jul 10;25:e47612. doi: 10.2196/47612.
9
RDS-NExT workshop: consensus statements for the use of surfactant in preterm neonates with RDS.RDS-NExT 研讨会：关于早产儿 RDS 使用表面活性剂的共识声明。
J Perinatol. 2023 Aug;43(8):982-990. doi: 10.1038/s41372-023-01690-9. Epub 2023 May 15.
10
Risk prediction of bronchopulmonary dysplasia in preterm infants by the nomogram model.列线图模型对早产儿支气管肺发育不良的风险预测
Front Pediatr. 2023 Mar 14;11:1117142. doi: 10.3389/fped.2023.1117142. eCollection 2023.

本文引用的文献

1
Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis.在患有呼吸窘迫综合征的早产儿中，与插管给药相比，采用侵入性较小的表面活性剂给药方式：一项系统评价和荟萃分析。
Arch Dis Child Fetal Neonatal Ed. 2017 Jan;102(1):F17-F23. doi: 10.1136/archdischild-2015-310299. Epub 2016 Nov 15.
2
European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2016 Update.《欧洲呼吸窘迫综合征管理共识指南 - 2016年更新》
Neonatology. 2017;111(2):107-125. doi: 10.1159/000448985. Epub 2016 Sep 21.
3
Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants.用于预防和治疗早产儿呼吸窘迫综合征的动物源性表面活性剂的比较。
Cochrane Database Syst Rev. 2015 Dec 21;2015(12):CD010249. doi: 10.1002/14651858.CD010249.pub2.
4
Continuous positive airway pressure failure in preterm infants: incidence, predictors and consequences.早产儿持续气道正压通气失败：发生率、预测因素和后果。
Neonatology. 2013;104(1):8-14. doi: 10.1159/000346460. Epub 2013 Apr 4.
5
Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants.预防性与选择性使用表面活性剂预防早产儿发病和死亡的研究
Cochrane Database Syst Rev. 2001(2):CD000510. doi: 10.1002/14651858.CD000510.